Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.
Egypt has the highest prevalence of HCV worldwide (15%) with a high morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma. The Aim of this study was to investigate the associations between IL-28B single nucleotide polymorphisms (SNP rs12979860) and treatment outcome among Egyptian patients infected with HCV genotype 4. HCV patients were genotyped as CC, CT, or TT at the polymorphic site, rs12979860 in unrelated case control of Egyptian population with HCV. By using univariate regression analysis, the minor allele of IL28B (p < 0.0001), high serum level of HCV-RNA (p = 0.035), and advanced fibrosis (p = 0.02) were associated with (NRs) (Odds ratio, 3.75 with 95% confidence nterval (2.308-6.1067). While, in multivariate logistic regression analysis, rs12979860 CC genotype was the strongest predictive of SVR (OR = 20.83, 95% CI = 11.63- 37.04, p < 0.0001). The IL28B rs12979860 SNP is the strongest predictor of an SVR among Egyptian patients infected with HCV-4.